SS-31 Peptide (Elamipretide): Mitochondrial Research Data

What Is SS-31 (Elamipretide)?

SS-31, developed by Cornell pharmacologists Hazel Szeto and Peter Schiller (the initials “SS” refer to their surnames), is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-2’6’-Dmt-Lys-Phe-NH₂. It is also known by its clinical development name elamipretide, and by earlier investigational names Bendavia and MTP-131 (Mitochondria-Targeting Peptide-131).

The compound belongs to the Szeto-Schiller class of cell-penetrating peptides characterised by an alternating aromatic-cationic architecture. Unlike conventional mitochondria-targeting compounds (such as MitoQ or triphenylphosphonium-conjugated antioxidants, which rely on the mitochondrial membrane potential to drive accumulation in the matrix), SS-31 targets the inner mitochondrial membrane itself — specifically concentrating at cardiolipin-rich cristae junctions where the electron transport chain complexes reside.

The molecular formula is C₃₂H₄₉N₉O₅, with a molecular weight of approximately 639.8 g/mol. SS-31 is water-soluble, stable in physiological conditions, and achieves inner mitochondrial membrane concentrations approximately 100-fold higher than the cytosol in cell studies — a pharmacokinetic property that enables therapeutic action at the specific subcellular compartment where mitochondrial dysfunction originates.

Stealth BioTherapeutics (Cambridge, MA; renamed Mighty Therapeutics in June 2026) licensed and developed elamipretide through Phase 2 and Phase 3 clinical programmes. In September 2025 FDA granted elamipretide accelerated approval as Forzinity for Barth syndrome, which makes SS-31 the most clinically advanced compound in its mitochondria-targeted class. For research purposes, SS-31 is available as a lyophilised powder for in-vitro and ex-vivo experimental use.

How SS-31 Targets Mitochondria: Cardiolipin Binding

Cardiolipin is a structurally unique phospholipid found almost exclusively in the inner mitochondrial membrane, where it constitutes approximately 20% of the total lipid content. It carries an unusual dimeric phosphate headgroup structure — two phosphate groups connected by a glycerol backbone, each esterified to two acyl chains — giving cardiolipin four acyl chains and two negative charges at physiological pH. This anionic character creates the electrostatic environment that recruits SS-31 to the membrane surface.

Birk et al. (2013, J Am Soc Nephrol) provided the first direct molecular characterisation of SS-31–cardiolipin binding using solution NMR spectroscopy and fluorescence displacement assays. The study demonstrated that SS-31 binds cardiolipin through a dual-mode interaction:

• Electrostatic anchoring: The D-Arg and Lys residues carry positive charges that interact with the anionic phosphate headgroups of cardiolipin, anchoring the peptide to the membrane surface.
• Hydrophobic insertion: The 2’6’-Dmt (dimethyltyrosine) and Phe aromatic side chains intercalate into the acyl chain region of the cardiolipin lipid bilayer, embedding the peptide at the membrane interface without crossing it.

This positioning is structurally critical. Cardiolipin is concentrated at the cristae junctions of the inner mitochondrial membrane — the narrow tubular invaginations where the respiratory chain complexes (Complexes I through IV) and ATP synthase (Complex V) are physically organised into supercomplexes called respirasomes. The curvature of cristae membranes is itself cardiolipin-dependent: cardiolipin stabilises the tightly curved inner membrane geometry that brings the electron transport chain complexes into optimal proximity for electron transfer. When cardiolipin is oxidised, depleted, or its acyl chain composition shifts (as in Barth syndrome or aging), cristae architecture collapses, respirasome organisation is disrupted, and ATP production efficiency falls.

By binding selectively to cardiolipin at these cristae junctions, SS-31 does not simply act as a generic antioxidant — it functions as a structural stabiliser of the inner mitochondrial membrane environment where electron transport occurs.

Mechanism of Action: ATP Production and Electron Transport

Electron Transport Chain Stabilisation

The electron transport chain (ETC) consists of four protein complexes (I–IV) embedded in the inner mitochondrial membrane that sequentially transfer electrons from NADH and FADH₂ to molecular oxygen, creating a proton gradient across the inner membrane. This electrochemical gradient — the mitochondrial membrane potential (ΔΨ_m) — drives ATP synthase to phosphorylate ADP to ATP. In conditions of mitochondrial dysfunction, ETC complex activity decreases, electron leakage increases, and the resulting uncoupled electrons react with oxygen to produce reactive oxygen species (ROS) — primarily superoxide.

SS-31 stabilises the structural organisation of ETC complexes by protecting the cardiolipin scaffold on which they depend. Szeto (2014, Biochim Biophys Acta) demonstrated that SS-31 treatment in isolated mitochondria exposed to oxidative stress preserved respiratory chain complex activity and maintained ΔΨ_m at levels significantly closer to non-stressed controls. Cellular energy (ATP) production rates were maintained even when mitochondria were subjected to conditions mimicking ischaemic stress.

ROS Reduction and Cardiolipin Protection

Cardiolipin is particularly susceptible to oxidative damage because of its four polyunsaturated acyl chains and its proximity to the primary sites of mitochondrial ROS generation (Complex I and Complex III). Oxidised cardiolipin cannot form the tight curvature of normal cristae, disrupting respirasome assembly and reducing electron transfer efficiency. This creates a self-amplifying cycle: ROS oxidises cardiolipin → cristae collapse → ETC disorganisation → more ROS generation.

The 2’6’-Dmt residue of SS-31 has intrinsic free radical scavenging capacity, acting as an electron donor to neutralise reactive oxygen species at the membrane surface. This antioxidant activity — positioned directly at the cardiolipin-ETC interface rather than in the aqueous matrix — is mechanistically distinct from matrix-targeted antioxidants like MitoQ and represents a key advantage of SS-31’s membrane-localised mechanism.

Cristae Structure and ATP Synthase Efficiency

Beyond electron transfer, the physical conformation of cristae membrane affects ATP synthase (Complex V) orientation and dimer formation. ATP synthase dimers line the highly curved edges of cristae, and their dimerisation is cardiolipin-dependent. Disrupted cardiolipin leads to ATP synthase monomerisation, which reduces rotor efficiency and lowers ATP output per unit proton gradient. Ikon and Ryan (2017, Chemistry and Physics of Lipids) detailed the cardiolipin–ATP synthase relationship and the implications for mitochondrial biogenesis and membrane remodelling. SS-31 treatment in experimental models preserved ATP synthase dimer formation in cardiolipin-deficient conditions, with corresponding restoration of cellular energy output.

A related functional benefit is on the adenine nucleotide translocator (ANT), the inner membrane carrier that exchanges ADP for newly synthesised ATP. ANT activity depends on the surrounding cardiolipin microenvironment — oxidised or depleted cardiolipin reduces ANT efficiency, creating a bottleneck between ATP synthesis and cytosolic ATP delivery. SS-31’s cardiolipin-protective action therefore extends to maintaining ANT transport kinetics, ensuring synthesised ATP is efficiently exported to meet cellular energy demands.

The net result of SS-31 action in experimental systems: improved coupling of the electron transport chain, reduced ROS leak, preserved mitochondrial membrane potential, and restored ATP production capacity — all achieved without crossing the inner membrane and without interfering with normal mitochondrial biogenesis signalling.

SS-31 Research in Aging and Muscle Function

The main human study of SS-31 in aging muscle is a 2021 randomised, double-blind, placebo-controlled trial by Roshanravan et al., published in PLOS ONE. It asked whether age-related mitochondrial dysfunction in skeletal muscle is fixed structural decay, or a state that can change quickly when the inner membrane environment is targeted.

The trial enrolled 39 adults aged 60 to 85 with poorly functioning mitochondria in the first dorsal interosseous (hand) muscle, measured non-invasively by in vivo ³¹P magnetic resonance and optical spectroscopy. Participants received a single 2-hour IV infusion of elamipretide (n = 19) or placebo (n = 20) in parallel groups. The primary outcome was maximal mitochondrial ATP production (ATP_max), measured right after the infusion. The key finding: ATP_max rose relative to placebo after a single infusion, a borderline result (P = 0.045 for the percentage change, P = 0.055 for the absolute change). No difference remained on day 7, resting mitochondrial coupling did not change, and muscle fatigue resistance did not improve.

The implication is mechanistically important. Aging-related sarcopenia has long been attributed to accumulated mitochondrial DNA mutations, irreversible Complex I damage, and progressive mitochondrial biogenesis failure. The authors describe the result as the first demonstration that a drug can reverse mitochondrial dysfunction in aging human muscle immediately after treatment. It is consistent with the idea that part of age-related mitochondrial dysfunction reflects acute, correctable deterioration of the inner membrane environment — specifically the cardiolipin composition and cristae architecture that SS-31 directly targets. The study was small, single-dose and borderline. If confirmed in larger and longer studies, this would reposition mitochondrial membrane biology as a primary driver of the aging muscle phenotype, rather than a secondary consequence of irreversible damage.

The human trial built on mouse work by Siegel et al. (Aging Cell, 2013). One hour after a single SS-31 dose, aged mice showed resting and maximal mitochondrial ATP production, oxidative-phosphorylation coupling (P/O) and cell energy state (PCr/ATP) restored toward young levels, with a more reduced glutathione redox state and lower mitochondrial H₂O₂ emission. Their muscle was more fatigue resistant in situ, and eight days of treatment increased whole-animal endurance. Young muscle showed no effect.

SS-31 and Sarcopenia Research

Sarcopenia — the progressive loss of skeletal muscle mass and function with aging — represents a major public health burden. Mitochondrial dysfunction is a proposed mechanistic driver: reduced ATP availability impairs muscle protein synthesis, decreases exercise capacity (reducing anabolic stimulus), and may directly promote atrophic signalling through mitochondrial ROS. SS-31 research in sarcopenia-relevant models has demonstrated improvements in muscle fibre cross-sectional area, mitochondrial density, and functional performance metrics in aged rodent models. Human data remain limited to the single-dose Roshanravan et al. trial, with no published large-scale sarcopenia intervention trial as of October 2026.

Cardiac Research Applications

Ischaemia-Reperfusion Injury

Cardiac ischaemia-reperfusion (IR) injury — the paradoxical cellular damage that occurs when blood flow is restored to ischaemic heart tissue — involves massive mitochondrial dysfunction as its primary mechanism. Reperfusion drives a rapid collapse of mitochondrial membrane potential, opening of the mitochondrial permeability transition pore (mPTP), and a burst of ROS generation that destroys cardiomyocytes. Cardiolipin oxidation is one of the earliest events in IR-induced mitochondrial damage, preceding mPTP opening.

Szeto et al. (2006, AAPS Journal) and subsequent studies demonstrated that SS-31 administration before reperfusion significantly reduced infarct size in rat and pig IR models. The mechanism was cardiolipin protection: SS-31 at the inner membrane surface intercepted ROS before they could oxidise cardiolipin, preventing cristae collapse and mPTP opening. Szeto (2014, Br J Pharmacol) framed the accumulating cardiac data as evidence that cardiolipin-targeted therapy with elamipretide represents a mechanistically sound approach to IR protection — distinct from ATP-preservation strategies and antioxidant therapies that had previously failed in large cardiac trials because they targeted the wrong compartment.

Heart Failure Research

Stealth BioTherapeutics conducted PROGRESS-HF — a Phase 2 randomised trial evaluating 4 weeks of subcutaneous elamipretide versus placebo in patients with heart failure with reduced ejection fraction (HFrEF). The primary endpoint was left ventricular end-systolic volume index (LVESVi). Results published in 2020 showed a non-significant trend toward LV remodelling improvement in the elamipretide arm, with separation from placebo most evident in patients with elevated baseline cardiolipin biomarkers. The trial was underpowered for definitive conclusions but provided proof-of-mechanism signals consistent with the cardiolipin hypothesis.

Mitochondrial dysfunction in chronic heart failure is well-established: failing cardiomyocytes show reduced Complex I activity, decreased cardiolipin content, disordered cristae, and impaired fatty acid oxidation. The heart’s near-total dependence on oxidative phosphorylation (90% of cardiac ATP comes from mitochondrial respiration) makes it uniquely vulnerable to inner membrane disruption — and uniquely dependent on compounds like SS-31 that address the structural root cause.

Barth Syndrome: Cardiolipin Deficiency Disease

Barth syndrome is an X-linked disorder caused by loss-of-function mutations in the TAZ gene, which encodes tafazzin — an enzyme required for remodelling cardiolipin acyl chains to the mature tetralinoleoyl cardiolipin (TLCL) form. Without functional tafazzin, immature cardiolipin species (monolysocardiolipin, dilysocardiolipin) accumulate and mature TLCL is depleted. The result is severe mitochondrial dysfunction affecting heart (dilated cardiomyopathy), skeletal muscle (myopathy), and neutrophil function. Barth syndrome represents a proof-of-concept disease for the cardiolipin hypothesis: it is mitochondrial dysfunction caused directly and specifically by cardiolipin abnormality.

This mechanistic alignment makes Barth syndrome the ideal indication for elamipretide testing. TAZPOWER did not meet either primary endpoint in its blinded crossover period. The subsequent open-label extension reported a 95.9-metre improvement in 6-minute walk distance from baseline at week 36 among the eight participants who reached that visit. FDA later granted accelerated approval to Forzinity for Barth syndrome based on the broader evidence package, with confirmatory evidence required.

Kidney and Metabolic Research

Renal Ischaemia and Acute Kidney Injury

The kidney is the second most mitochondria-dense organ after the heart, with proximal tubular cells depending almost entirely on oxidative phosphorylation for their ATP. Renal ischaemia — whether from haemodynamic shock, cardiac surgery, or contrast nephropathy — produces mitochondrial dysfunction that drives acute kidney injury (AKI). Elamipretide has been studied in multiple renal ischaemia models, demonstrating preservation of tubular cell mitochondrial function, reduced oxidative stress markers, and improved renal function recovery in preclinical studies.

Szeto et al. conducted human proof-of-concept studies in patients at high risk for contrast-induced AKI. In a Phase 2 trial (NCT02436447), patients receiving IV elamipretide before and after cardiac catheterisation showed trends toward reduced incidence of AKI compared to placebo, with the greatest signal in patients with pre-existing chronic kidney disease whose baseline mitochondrial function was most compromised. These findings were hypothesis-generating rather than definitive.

Metabolic Syndrome and Insulin Resistance

Mitochondrial dysfunction in skeletal muscle is mechanistically linked to insulin resistance — impaired ATP production from fatty acid oxidation leads to intramyocellular lipid accumulation (diacylglycerol, ceramides) that inhibits insulin signalling through PKCΘ activation. SS-31 research in metabolic syndrome models (diet-induced obese mice) demonstrated improvements in mitochondrial fatty acid oxidation capacity, reduced intramyocellular lipid accumulation, and improved insulin sensitivity — effects mediated through restoration of inner membrane ETC function rather than direct insulin signalling pathway modulation. These findings position mitochondrial membrane biology as a potential upstream target in metabolic disease, though we found no published human metabolic syndrome trial data for SS-31 as of October 2026.

SS-31 vs MOTS-c vs Humanin: Mitochondrial Peptide Comparison

Three classes of mitochondria-associated peptides have attracted significant research interest: the synthetic inner membrane-targeting SS peptides (SS-31 being the lead compound), and the mitochondrial DNA-encoded peptides MOTS-c and Humanin. Each targets mitochondrial biology through fundamentally different mechanisms and at different subcellular levels.

The key distinction of SS-31 versus the other entries is its structural rather than purely antioxidant mechanism. SS-31 acts at the cardiolipin–ETC interface, stabilising the architecture that allows efficient electron transfer and ATP production. MOTS-c and Humanin act at the level of gene regulation and extracellular signalling — they modulate the cellular response to mitochondrial stress rather than the structural mitochondrial environment itself. MitoQ and SkQ1 scavenge ROS in the matrix but do not address the cardiolipin structural defects that drive inner membrane dysfunction. This mechanistic specificity underpins the unique clinical rationale for SS-31 in cardiolipin-deficiency diseases like Barth syndrome.

Clinical Trial Status

Elamipretide has the most extensive clinical trial portfolio of any mitochondria-targeted compound. As of May 2026, the following Phase 2/3 programmes are completed or ongoing — with the September 2025 Forzinity approval now anchoring the Barth syndrome indication:

The pattern across these trials reveals a consistent mechanism signal without a dominant therapeutic success story to date. Elamipretide has met its primary endpoint in relatively few of the above trials (even in Barth syndrome, the clearest signal, TAZPOWER’s blinded primary endpoints were not met; the gains came in the open-label extension), while showing consistent secondary endpoint signals and mechanistically aligned biomarker changes across the others. This pattern is consistent with inadequate statistical power (small sample sizes) and patient selection challenges rather than mechanism failure — but it has created headwinds for regulatory approval in indications beyond Barth syndrome.

Stealth BioTherapeutics faced significant financial difficulties in 2022–2023, and the elamipretide intellectual property and clinical dataset transitioned through several restructuring steps before the company resurfaced as the sponsor of the eventual approval programme. In June 2026 Stealth BioTherapeutics renamed itself Mighty Therapeutics. Researchers should consult ClinicalTrials.gov for current registered trials (search: elamipretide, SS-31, MTP-131).

Forzinity — first FDA accelerated approval (September 19, 2025)

The FDA granted accelerated approval to Forzinity (elamipretide hydrochloride) on September 19, 2025 — the first treatment for Barth syndrome, indicated to improve muscle strength in patients weighing 30 kg or more. FDA based the accelerated approval on improved knee extensor (leg-straightening) muscle strength, an intermediate endpoint it considers reasonably likely to predict benefit; a randomised, placebo-controlled confirmatory trial is required as a condition of the accelerated pathway. Source: FDA Press Announcement, September 19, 2025.

The ophthalmology programme has also moved. The global Phase 3 ReNEW study (NCT06373731) of elamipretide for dry age-related macular degeneration hit its 50% enrollment milestone on March 13, 2025 and has since closed enrolment: ClinicalTrials.gov (record verified September 2026) lists it as active, not recruiting, with 313 participants enrolled and primary completion estimated for August 2027, so no Phase 3 readout is expected before then (NCT06373731). With the parallel ReGAIN trial, it is the largest pivotal programme outside Barth syndrome. The FDA separately granted Fast Track designation to topical elamipretide eye drops for Leber hereditary optic neuropathy (LHON), opening a second ophthalmology indication beyond AMD. Sources: Stealth IR release, March 13, 2025; American Academy of Ophthalmology, 2025.

Safety and Tolerability Profile

Elamipretide has undergone formal tolerability assessment in multiple Phase 1 and Phase 2 clinical trials, accumulating a human safety dataset across diverse patient populations including healthy volunteers, patients with heart failure, Barth syndrome patients (including paediatric), and elderly individuals with age-related mitochondrial dysfunction.

Injection Site Reactions (Subcutaneous Administration)

The most consistently reported observations in SC elamipretide studies are localised injection site reactions: erythema (redness), pruritus (itching), and mild pain or induration at the administration site. In the TAZPOWER trial, injection site reactions were the most common adverse event and occurred in the majority of elamipretide-treated participants. These reactions were predominantly Grade 1 (mild) and Grade 2 (moderate), were transient, and did not result in study discontinuation in the reported data. The reactions appear to reflect the peptide’s cationic character at the injection site rather than systemic immune activation.

Systemic Observations

Across Phase 2 trials, systemic adverse events were not significantly different from placebo in blinded assessments. No dose-limiting cardiac, hepatic, renal, or haematological toxicity has been identified in published trials. In the single-dose aging-muscle trial (Roshanravan et al., 2021), the ClinicalTrials.gov record (NCT02245620) lists no serious adverse events in either arm (0 of 19 on elamipretide, 0 of 20 on placebo). The compound does not appear to affect mitochondrial membrane potential in non-dysfunctional cells, consistent with its mechanism — cardiolipin binding is pharmacologically inert in cells where inner membrane integrity is maintained and ROS generation is low.

Paediatric Tolerability

TAZPOWER enrolled males aged 12 and older weighing more than 30 kg, so it provides no safety data in younger children. SS-31’s peptide nature (enzymatic degradation to amino acids) and its membrane-localised action without nuclear penetration suggest a low intrinsic toxicity profile, but that is a mechanistic expectation, not a paediatric safety finding.

All tolerability information above derives from controlled research trial data. SS-31 is a research compound — this section does not constitute a safety evaluation for any use outside an approved research or clinical context.

The Future of Mitochondrial Medicine

SS-31 represents the leading edge of a rethink in how researchers approach the relationship between mitochondrial biology and disease. The conventional view — that mitochondria matter primarily as energy factories whose dysfunction is a downstream consequence of disease — is being replaced by evidence that mitochondrial membrane integrity, cardiolipin composition, and cristae architecture are primary, upstream drivers of cellular function across multiple organ systems.

Cardiolipin as the Master Regulator

Cardiolipin has emerged as a central node in mitochondrial biology that extends beyond energy production. Research has identified cardiolipin roles in: apoptosis initiation (cardiolipin oxidation is the signal for cytochrome c release), mitophagy (damaged mitochondria are labelled by surface cardiolipin for autophagic elimination via PINK1/Parkin), mitochondrial biogenesis (cardiolipin is required for import of nuclear-encoded mitochondrial proteins), and innate immune signalling (oxidised cardiolipin activates NLRP3 inflammasome in macrophages). SS-31’s cardiolipin-targeting mechanism thus has ramifications extending into apoptosis regulation, immune function, and mitochondrial quality control — research territory that has barely been explored.

Mitochondria-Targeted Therapeutics Pipeline

The success — even partial success — of elamipretide in multiple clinical programmes has inspired a broader mitochondria-targeted therapeutic pipeline. Current research areas include:

• NAD+ precursors (NMN, NR): Support mitochondrial biogenesis through SIRT1/SIRT3 deacetylase activation and complex I substrate provision. Several human trials underway.
• Coenzyme Q10 analogues (MitoQ, SkQ1): Matrix-targeted ROS scavengers with differentiated subcellular localisation from SS-31.
• Mitochondrial uncouplers (BAM15, DNP analogues): Controlled proton leak to reduce ROS without collapsing ΔΨ_m. Active preclinical programmes.
• MOTS-c and Humanin analogues: Optimised variants of mitochondrial DNA-encoded peptides for metabolic and neuroprotective applications.
• Gene therapy for Barth syndrome: AAV-TAZ constructs to restore tafazzin function — the upstream fix for the cardiolipin remodelling defect that elamipretide addresses downstream.

SS-31 occupies a unique position in this landscape: it is the only compound with a completed randomised clinical trial dataset specifically targeting the structural cardiolipin environment of the inner mitochondrial membrane. The mechanistic specificity — binding to the precise lipid scaffold on which the electron transport chain depends — provides a research template that has validated cardiolipin as a druggable target and opened a new chapter in mitochondrial medicine.

From the perspective of aging research, the Roshanravan et al. 2021 findings carry the most far-reaching implications. If age-related mitochondrial dysfunction in muscle is primarily a correctable membrane environment problem rather than irreversible oxidative damage or mtDNA mutation accumulation, then interventions targeting cardiolipin integrity could substantially alter the trajectory of musculoskeletal aging. This remains an active and unresolved research question — but the single-dose SS-31 trial gives early, borderline controlled evidence that it may be.